SCRIPPS RESEARCH INSTITUTE

• TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE

  UEI GM1XX56LEP58

  $912.7K

  Subcontractor to this prime · 2 sub-awards · latest Apr 6, 2026

  • National Institutes of Health
  • “IN THIS PROJECT, WE WILL STRUCTURALLY AND BIOPHYSICALLY CHARACTERIZE NEUTRALIZING ANTIBODIES AND IMMUNE SERA DERIVED FROM NATURAL INFECTION BY INFLUENZA VIRUS AND FROM VACCINATION. THE WILSON LAB WILL EXPRESS AND PURIFY ANTIBODIES, ANTIGENS AND IMMUNOGENS FROM MAMMALIAN CELL LINES, INCLUDING 293S, 293T AND 293F CELLS, DROSOPHILA CELLS, OR E. COLI FOR STRUCTURAL AND BIOPHYSICAL STUDIES. WE WILL THEN STRUCTURALLY AND BIOPHYSICALLY ANALYZE THESE NEUTRALIZING ANTIBODIES WITH INFLUENZA ANTIGENS [HEMAGGLUTININ (HA), AND NEURAMINIDASE (NA)], AS WELL AS IDENTIFIED RESISTANCE MUTANTS, TO DETERMINE ANTIBODY AFFINITIES AND MODE OF BINDING, STABILITY, STOICHIOMETRY, EPITOPES AND 3D STRUCTURES. WE WILL USE X-RAY CRYSTALLOGRAPHY TO DETERMINE THE HIGH-RESOLUTION STRUCTURES OF ANTIBODIES AND ANTIBODY-ANTIGEN COMPLEXES. OTHER BIOPHYSICAL METHODS INCLUDING BIO-LAYER INTERFEROMETRY (BLI), ISOTHERMAL TITRATION CALORIMETRY ITC), DIFFERENTIAL SCANNING CALORIMETRY (DSC) AND SURFACE PLASMON RESONANCE (SPR), WILL BE USED TO DETERMINE BINDING AFFINITIES AND PROTEIN/IMMUNOGEN STABILITY. WE WILL DESIGN, MODIFY AND CHARACTERIZE IMMUNOGENS AS VACCINES CANDIDATES USING STRUCTURE-ASSISTED VACCINE DESIGN METHODS THAT WE HAVE PREVIOUSLY SUCCESSFULLY UTILIZED FOR HIV, INFLUENZA VIRUS AND HEPATITIS C VIRUS. THE WARD LAB WILL UTILIZE THEIR RECENTLY DEVELOPED NOVEL EM IMAGING METHOD OF POLYCLONAL EPITOPE MAPPING (EMPEM) TO ANALYZE POLYCLONAL ANTIBODY RESPONSES IN SERA TO IDENTIFY PATTERNS OF EPITOPE UTILIZATION AND FREQUENCY IN HA AND NA IN HUMAN LONGITUDINAL COHORTS. THE HA OR NA PROTEIN PROBES IN THESE ANALYSES WILL BE PRODUCED IN THE WILSON LAB AND SERA PROVIDED BY OUR COLLEAGUES IN THIS CEIRR PROJECT.”
  • “STATEMENT OF WORK FOR WILSON AND WARD LABS IN THIS PROJECT, WE WILL STRUCTURALLY AND BIOPHYSICALLY CHARACTERIZE NEUTRALIZING ANTIBODIES AND IMMUNE SERA DERIVED FROM NATURAL INFECTION BY INFLUENZA VIRUS AND FROM VACCINATION. THE WILSON LAB WILL EXPRESS AND PURIFY ANTIBODIES, ANTIGENS AND IMMUNOGENS FROM MAMMALIAN CELL LINES, INCLUDING 293S, 293T AND 293F CELLS, DROSOPHILA CELLS, OR E. COLI FOR STRUCTURAL AND BIOPHYSICAL STUDIES. WE WILL THEN STRUCTURALLY AND BIOPHYSICALLY ANALYZE THESE NEUTRALIZING ANTIBODIES WITH INFLUENZA ANTIGENS [HEMAGGLUTININ (HA), AND NEURAMINIDASE (NA)], AS WELL AS IDENTIFIED RESISTANCE MUTANTS, TO DETERMINE ANTIBODY AFFINITIES AND MODE OF BINDING, STABILITY, STOICHIOMETRY, EPITOPES AND 3D STRUCTURES. WE WILL USE X-RAY CRYSTALLOGRAPHY TO DETERMINE THE HIGH-RESOLUTION STRUCTURES OF ANTIBODIES AND ANTIBODY-ANTIGEN COMPLEXES. OTHER BIOPHYSICAL METHODS INCLUDING BIO-LAYER INTERFEROMETRY (BLI), ISOTHERMAL TITRATION CALORIMETRY ITC), DIFFERENTIAL SCANNING CALORIMETRY (DSC) AND SURFACE PLASMON RESONANCE (SPR), WILL BE USED TO DETERMINE BINDING AFFINITIES AND PROTEIN/IMMUNOGEN STABILITY. WE WILL DESIGN, MODIFY AND CHARACTERIZE IMMUNOGENS AS VACCINES CANDIDATES USING STRUCTURE-ASSISTED VACCINE DESIGN METHODS THAT WE HAVE PREVIOUSLY SUCCESSFULLY UTILIZED FOR HIV, INFLUENZA VIRUS AND HEPATITIS C VIRUS. THE WARD LAB WILL UTILIZE THEIR RECENTLY DEVELOPED NOVEL EM IMAGING METHOD OF POLYCLONAL EPITOPE MAPPING (EMPEM) TO ANALYZE POLYCLONAL ANTIBODY RESPONSES IN SERA TO IDENTIFY PATTERNS OF EPITOPE UTILIZATION AND FREQUENCY IN HA AND NA IN HUMAN LONGITUDINAL COHORTS. THE HA OR NA PROTEIN PROBES IN THESE ANALYSES WILL BE PRODUCED IN THE WILSON LAB AND SERA PROVIDED BY OUR COLLEAGUES IN THIS CEIRR PROJECT.”
• THE ADMINISTRATORS OF TULANE EDUCATIONAL FUND

  UEI XNY5ULPU8EN6

  $687.5K

  Subcontractor to this prime · 1 sub-award · latest Oct 22, 2024

  • National Institutes of Health
  • “THE SUBCONTRACTOR LAB WILL HELP COLLEAGUES WITH THE PRODUCTION, PURIFICATION, AND CHARACTERIZATION OF THE IMMUNOGENS FOR THE STUDY, INCLUDING THE REAGENTS NEEDED FOR ELISA AND BIOLAYER INTERFEROMETRY ASSAYS (BLI) TO ASSESS ANTIBODY AFFINITY, AND VIRUSES TO BE TESTED FOR TZM-BL HIV-1 NEUTRALIZATION ASSAY. WE WILL ALSO PROVIDE THE REAGENTS AND SUPPLIES NEEDED FOR ANTIGEN SPECIFIC B CELL SORTING TO OBTAIN AND GENERATE ENV-SPECIFIC B CELL CLONES AND WITH A FOCUS ON IDENTIFYING CLONES TARGETING ENV FUSION PEPTIDE. WE WILL SCREEN ANIMALS FOR VIRUS SPECIFIC RESPONSES AND ASSESS BINDING SITES TO ASSESS SPECIFICITY AND BREADTH OF PROTECTION”
• THE LELAND STANFORD JUNIOR UNIVERSITY

  UEI HJD6G4D6TJY5

  $201.3K

  Subcontractor to this prime · 1 sub-award · latest Jan 16, 2026

  • National Institutes of Health
  • “INNOVATIONS IN FUNCTIONAL B-CELL EPITOPE DISCOVERY IN FOOD ALLERGENS”

No reported sub-awards as a prime contractor.

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.